1 |
Cheifetz, S., T. Bellon, C. Cales, S. Vera, C. Bernabeu, J. Massague, and M. Letarte. 1992. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J. Biol. Chem. 267: 19027-19030.
|
2 |
Gougos, A., and M. Letarte. 1990. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J. Biol. Chem. 265: 8361-8364.
|
3 |
Fernandez-Ruiz, E., S. St-Jacques, T. Bellon, M. Letarte, and C. Bernabeu. 1993. Assignment of the human endoglin gene (END) to 9q34 qter. Cytogenet. Cell Genet. 64: 204-207.
DOI
|
4 |
St-Jacques, S., U. Cymerman, N. Pece, and M. Letarte. 1994. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology 134: 2645-2657.
DOI
|
5 |
Bellon, T., A. Corbi, P. Lastres, C. Cales, M. Cebrian, S. Vera, S. Cheifetz, J. Massague, M. Letarte, and C. Bernabeu. 1993. Identification and expression of two forms of the human transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur. J. Immunol. 23: 2340-2345.
DOI
ScienceOn
|
6 |
Hawinkels, L. J., P. Kuiper, E. Wiercinska, H. W. Verspaget, Z. Liu, E. Pardali, C. F. Sier, and P. ten Dijke. 2010. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res. 70: 4141-4150.
DOI
|
7 |
Conley, B. A., J. D. Smith, M. Guerrero-Esteo, C. Bernabeu, and C. P. Vary. 2000. Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques. Atherosclerosis 153: 323-335.
DOI
|
8 |
Sanchez-Elsner, T., L. M. Botella, B. Velasco, C. Langa, and C. Bernabeu. 2002. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J. Biol. Chem. 277: 43799-43808.
DOI
|
9 |
Lastres, P., A. Letamendia, H. Zhang, C. Rius, N. Almendro, U. Raab, L. A. Lopez, C. Langa, A. Fabra, M. Letarte, and C. Bernabeu. 1996. Endoglin modulates cellular responses to TGF-beta 1. J. Cell Biol. 133: 1109-1121.
DOI
|
10 |
Ikemoto, T., Y. Hojo, H. Kondo, N. Takahashi, M. Hirose, Y. Nishimura, T. Katsuki, K. Shimada, and K. Kario. 2012. Plasma endoglin as a marker to predict cardiovascular events in patients with chronic coronary artery diseases. Heart Vessels 27: 344-351.
DOI
|
11 |
Santibanez, J. F., M. Quintanilla, and C. Bernabeu. 2011. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond.) 121: 233-251.
DOI
|
12 |
Guerrero-Esteo, M., T. Sanchez-Elsner, A. Letamendia, and C. Bernabeu. 2002. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J. Biol. Chem. 277: 29197-29209.
DOI
ScienceOn
|
13 |
ten Dijke, P., M. J. Goumans, and E. Pardali. 2008. Endoglin in angiogenesis and vascular diseases. Angiogenesis 11: 79-89.
DOI
|
14 |
Tian, F., A. X. Zhou, A. M. Smits, E. Larsson, M. J. Goumans, C. H. Heldin, J. Boren, and L. M. Akyurek. 2010. Endothelial cells are activated during hypoxia via endoglin/ALK-1/SMAD1/5 signaling in vivo and in vitro. Biochem. Biophys. Res. Commun. 392: 283-288.
DOI
|
15 |
Blanco, F. J., J. F. Santibanez, M. Guerrero-Esteo, C. Langa, C. P. Vary, and C. Bernabeu. 2005. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J. Cell Physiol. 204: 574-584.
DOI
|
16 |
Llorca, O., A. Trujillo, F. J. Blanco, and C. Bernabeu. 2007. Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J. Mol. Biol. 365: 694-705.
DOI
ScienceOn
|
17 |
Blanco, F. J., M. T. Grande, C. Langa, B. Oujo, S. Velasco, A. Rodriguez-Barbero, E. Perez-Gomez, M. Quintanilla, J. M. Lopez-Novoa, and C. Bernabeu. 2008. S-endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ. Res. 103: 1383-1392.
DOI
|
18 |
Gamble, J. R., Y. Khew-Goodall, and M. A. Vadas. 1993. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J. Immunol. 150: 4494-4503.
|
19 |
Post, S., W. Peeters, E. Busser, D. Lamers, J. P. Sluijter, M. J. Goumans, R. A. de Weger, F. L. Moll, P. A. Doevendans, G. Pasterkamp, and A. Vink. 2008. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J. Vasc. Res. 45: 244-250.
DOI
|
20 |
Blazquez-Medela, A. M., L. Garcia-Ortiz, M. A. Gomez-Marcos, J. I. Recio-Rodriguez, A. Sanchez-Rodriguez, J. M. Lopez-Novoa, and C. Martinez-Salgado. 2010. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 8: 86.
DOI
|
21 |
Li, C. G., H. Bethell, P. B. Wilson, D. Bhatnagar, M. G. Walker, and S. Kumar. 2000. The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis 152: 249-256.
DOI
|
22 |
Massague, J., and D. Wotton. 2000. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 19: 1745-1754.
DOI
ScienceOn
|
23 |
Singh, N. N., and D. P. Ramji. 2006. The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev. 17: 487-499.
DOI
|
24 |
Mallat, Z., A. Gojova, C. Marchiol-Fournigault, B. Esposito, C. Kamate, R. Merval, D. Fradelizi, and A. Tedgui. 2001. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89: 930-934.
DOI
ScienceOn
|
25 |
Feinberg, M. W., and M. K. Jain. 2005. Role of transforming growth factor-beta1/Smads in regulating vascular inflammation and atherogenesis. Panminerva Med. 47: 169-186.
|
26 |
Lebrin, F., M. Deckers, P. Bertolino, and P. Ten Dijke. 2005. TGF-beta receptor function in the endothelium. Cardiovasc. Res. 65: 599-608.
DOI
ScienceOn
|
27 |
Koleva, R. I., B. A. Conley, D. Romero, K. S. Riley, J. A. Marto, A. Lux, and C. P. Vary. 2006. Endoglin structure and function: Determinants of endoglin phosphorylation by transforming growth factor-beta receptors. J. Biol. Chem. 281: 25110-25123.
DOI
|
28 |
Venkatesha, S., M. Toporsian, C. Lam, J. Hanai, T. Mammoto, Y. M. Kim, Y. Bdolah, K. H. Lim, H. T. Yuan, T. A. Libermann, I. E. Stillman, D. Roberts, P. A. D'Amore, F. H. Epstein, F. W. Sellke, R. Romero, V. P. Sukhatme, M. Letarte, and S. A. Karumanchi. 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12: 642-649.
DOI
ScienceOn
|
29 |
Li, C., P. Mollahan, M. S. Baguneid, R. F. McMahon, P. Kumar, M. G. Walker, A. J. Freemont, and S. Kumar. 2006. A comparative study of neovascularisation in atherosclerotic plaques using CD31, CD105 and TGF beta 1. Pathobiology 73: 192-197.
DOI
|
30 |
Blann, A. D., J. M. Wang, P. B. Wilson, and S. Kumar. 1996. Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis 120: 221-226.
DOI
|
31 |
Li, C., B. Guo, S. Ding, C. Rius, C. Langa, P. Kumar, C. Bernabeu, and S. Kumar. 2003. TNF alpha down-regulates CD105 expression in vascular endothelial cells: a comparative study with TGF beta 1. Anticancer Res. 23: 1189-1196.
|